» Articles » PMID: 20658522

Lapatinib, a Dual HER1/HER2 Tyrosine Kinase Inhibitor, Augments Basal Cleavage of HER2 Extracellular Domain (ECD) to Inhibit HER2-driven Cancer Cell Growth

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2010 Jul 27
PMID 20658522
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The ultimate biological and clinical meaning of shed HER2 extracellular domain (ECD) has remained largely unclear until recently. Oversecretion of soluble HER2 ECD has been shown to inhibit growth of HER2-overexpressing cancer cells by promoting HER2 ECD dimerization with HER transmembrane receptors thus impairing their cross-tyrosine phosphorylation and decreasing their activation status. HER2-targeted drugs capable to enhance the occurrence of basal HER2 ECD shedding but simultaneously preventing formation of truncated cell membrane-bound HER2 intracellular fragment, which exhibits an undesirable constitutive kinase activity, might be extremely efficient at managing HER2-positive cancer disease. The dual HER1/HER2 Tyrosine Kinase inhibitor lapatinib, which works intracellularly and directly targets the TK domain of HER2, drastically augments basal shedding of HER2 ECD to inhibit HER2-driven cancer cell growth. Lapatinib treatment significantly augments the concentration of the inactive (unphosphorylated) form of HER2 protein at the tumor cell membrane and promotes an exacerbated HER2 ECD shedding to the extracellular milieu of HER2-overexpressing cancer cells. Exacerbated sensitivity of trastuzumab-resistant cancer cells, which contain nearly undetectable levels of soluble HER2 ECD when compared with trastuzumab-sensitive parental cells to lapatinib-induced cell growth inhibition, takes place when lapatinib treatment fully restores high levels of basal HER2 ECD shedding. The dramatic augmentation of HER2 ECD shedding that occurs upon treatment of with lapatinib is fully suppressed in lapatinib-refractory HER2-positive cells. These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2-targeted drugs trastuzumab and lapatinib.

Citing Articles

Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer.

Yang Z, Feng J, Jing J, Huang Y, Ye W, Lei L NPJ Breast Cancer. 2023; 9(1):36.

PMID: 37160904 PMC: 10170158. DOI: 10.1038/s41523-023-00542-1.


Novel Small Multilamellar Liposomes Containing Large Quantities of Peptide Nucleic Acid Selectively Kill Breast Cancer Cells.

Proshkina G, Shramova E, Ryabova A, Katrivas L, Giannini C, Malpicci D Cancers (Basel). 2022; 14(19).

PMID: 36230729 PMC: 9564164. DOI: 10.3390/cancers14194806.


Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.

Collins D, Madden S, Gaynor N, Alsultan D, Le Gal M, Eustace A Clin Cancer Res. 2020; 27(3):807-818.

PMID: 33122343 PMC: 7854527. DOI: 10.1158/1078-0432.CCR-20-2007.


Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and -Mutated Breast Cancer.

Collins D, Conlon N, Kannan S, Verma C, Eli L, Lalani A Cancers (Basel). 2019; 11(6).

PMID: 31141894 PMC: 6628314. DOI: 10.3390/cancers11060737.


Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis.

Ma W, Zhao F, Zhou C, Zhang Y, Zhao Y, Li N Onco Targets Ther. 2019; 12:379-390.

PMID: 30655674 PMC: 6322707. DOI: 10.2147/OTT.S183304.